BioCentury
ARTICLE | Clinical News

Tivicay dolutegravir regulatory update

June 20, 2016 7:00 AM UTC

FDA approved an sNDA from ViiV for 10 and 25 mg tablets of Tivicay dolutegravir to treat HIV-1 infection and expanded the label to include patients ages 6-11 and reduce the weight limit to >=30 kg. Ti...